Department of Emergency Medicine and Trauma Center, Meyer University Children's Hospital, Florence, Italy.
Department of Orthopaedics and Traumatology, Meyer University Children's Hospital, Florence, Italy.
PLoS One. 2020 Dec 3;15(12):e0243314. doi: 10.1371/journal.pone.0243314. eCollection 2020.
Musculoskeletal (MSK) injuries are one of the most frequent reason for pain-related evaluation in the emergency department (ED) in children. There is still no consensus as to what constitutes the best analgesic for MSK pain in children. However, ibuprofen is reported to be the most commonly prescribed analgesic and is considered the standard first-line treatment for MSK injury pain in children, even if it is argued that it provides inadequate relief for many patients. The purpose of this study was to review the most recent literature to assess the efficacy of ibuprofen for pain relief in MSK injuries in children evaluated in the ED. We performed a systematic review of randomized controlled trials on pharmacological interventions in children and adolescents under 19 years of age with MSK injuries according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The primary outcome was the risk ratio for successful reduction in pain scores. Six studies met the inclusion criteria and provided data on 1028 children. A meta-analysis was not performed since studies were not comparable due to the different analgesic treatment used. No significant difference in term of main pain score reduction between all the analgesics used in the included studies was noted. Patients who received oral opioids had side effects more frequently when compared to children who received ibuprofen. The combination of effect on pain relief and tolerability would suggest ibuprofen as the initial drug of choice in providing relief from mild-to-moderate MSK pain in children in the ED. The results obtained in this review and current research suggest that there's no straightforward statistically significant evidence of the optimal analgesic agent to be used. However, ibuprofen may be preferable as the initial drug of choice in providing relief from MSK pain due to the favorable combination of effectiveness and safety profile. In fact, despite the non-significant pain reduction as compared to children who received opioids, there are less side effect associated to ibuprofen within studies. The wide range of primary outcomes measured in respect of pain scores and timing of recorded measures warrants a future standardization of study designs.
肌肉骨骼 (MSK) 损伤是儿童急诊科 (ED) 因疼痛相关评估的最常见原因之一。对于儿童的 MSK 疼痛,哪种镇痛剂效果最好,目前仍没有共识。然而,布洛芬被报道为最常开的止痛药,并且被认为是儿童 MSK 损伤疼痛的标准一线治疗药物,尽管有观点认为它不能为许多患者提供充分的缓解。本研究的目的是回顾最新的文献,评估布洛芬在 ED 评估的儿童 MSK 损伤中的止痛效果。我们根据系统评价和荟萃分析的首选报告项目 (PRISMA) 声明,对儿童和青少年 MSK 损伤的药理学干预的随机对照试验进行了系统评价。主要结局是疼痛评分成功降低的风险比。有 6 项研究符合纳入标准,提供了 1028 名儿童的数据。由于使用的不同镇痛治疗,研究之间没有可比性,因此未进行荟萃分析。纳入研究中使用的所有镇痛剂在主要疼痛评分降低方面没有显著差异。与接受布洛芬的儿童相比,接受口服阿片类药物的儿童更频繁地出现副作用。从缓解轻度至中度 MSK 疼痛的角度来看,将布洛芬作为儿童 ED 初始药物选择的缓解疼痛和耐受性的综合效果可能提示布洛芬作为初始药物选择。本综述和当前研究的结果表明,目前没有明确的证据表明哪种镇痛剂是最佳选择。然而,由于布洛芬的有效性和安全性良好,因此可能更适合作为缓解 MSK 疼痛的初始药物选择。事实上,尽管与接受阿片类药物的儿童相比,布洛芬的疼痛缓解程度不显著,但研究中布洛芬相关副作用较少。由于疼痛评分和记录测量时间的主要结局指标范围广泛,因此需要未来对研究设计进行标准化。